Skip to main content

Animations

MJFF Publications

6511 - 6520 of 8616 Results
Title
Year
  • Year
  • 2018
  • 2018
  • 2019
  • 2018
  • 2019
  • 2024
  • 2020
  • 2021
  • 2018
  • 2017
  • Summary Details
    RESTRICTED
    Title: A Phase 2a study of nilotinib in patients with advanced and early Parkinson’s disease. Study design (P5.068)
    Journal Name: Neurology
    Publisher: Ovid Technologies (Wolters Kluwer Health)
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1212/wnl.90.15_supplement.p5.068
    Best OA location URL:
    Citation Count: 0
  • Summary Details
    OPEN
    Title: Alpha-synuclein delays mitophagy and targeting Miro rescues neuron loss in Parkinson’s models
    Journal Name: Acta Neuropathologica
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1007/s00401-018-1873-4
    Citation Count: 132
  • Summary Details
    OPEN
    Title: Basic clinical features do not predict dopamine transporter binding in idiopathic REM behavior disorder
    Journal Name: npj Parkinson's Disease
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1038/s41531-018-0073-1
    Citation Count: 29
  • Summary Details
    RESTRICTED
    Title: Increased Brain Exposure of an Alpha-Synuclein Fibrillization Modulator by Utilization of an Activated Ester Prodrug Strategy
    Journal Name: ACS Chemical Neuroscience
    Publisher: American Chemical Society (ACS)
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1021/acschemneuro.8b00236
    Best OA location URL:
    Citation Count: 12
  • Summary Details
    OPEN
    Title: Mass Spectrometric Analysis of Lewy Body-Enriched α-Synuclein in Parkinson’s Disease
    Journal Name: Journal of Proteome Research
    Publisher: American Chemical Society (ACS)
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1021/acs.jproteome.8b00982
    Best OA location URL:
    Citation Count: 61
  • Summary Details
    OPEN
    Title: OFF episode quality of life impact scale (OFFELIA): A new measure of quality of life for off episodes in Parkinson's disease
    Journal Name: Parkinsonism & Related Disorders
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc-nd
    DOI - Digital Object Identifier: 10.1016/j.parkreldis.2024.106070
    Citation Count: 1
  • Summary Details
    OPEN
    Title: Clinical and Neuropathological Features Associated With Loss of RAB39B
    Journal Name: Movement Disorders
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1002/mds.27951
    Citation Count: 18
  • Summary Details
    OPEN
    Title: Prefrontal Physiomarkers of Anxiety and Depression in Parkinson’s Disease
    Journal Name: Frontiers in Neuroscience
    Publisher: Frontiers Media SA
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.3389/fnins.2021.748165
    Citation Count: 20
  • Summary Details
    OPEN
    Title: The LRRK2 Variant E193K Prevents Mitochondrial Fission Upon MPP+ Treatment by Altering LRRK2 Binding to DRP1
    Journal Name: Frontiers in Molecular Neuroscience
    Publisher: Frontiers Media SA
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.3389/fnmol.2018.00064
    Citation Count: 37
  • Summary Details
    OPEN
    Title: Ubiquitin Linkage-Specific Affimers Reveal Insights into K6-Linked Ubiquitin Signaling
    Journal Name: Molecular Cell
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1016/j.molcel.2017.08.020
    Citation Count: 178
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.